{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Moll T"],"funding":["NIDDK NIH HHS","NHLBI NIH HHS","National Institute for Health Research (NIHR)","NHGRI NIH HHS","Motor Neurone Disease Association","Wellcome Trust","Biotechnology and Biological Sciences Research Council","NIH HHS"],"pubmed_abstract":["New therapeutic targets are a valuable resource in the struggle to reduce the morbidity and mortality associated with the COVID-19 pandemic, caused by the SARS-CoV-2 virus. Genome-wide association studies (GWAS) have identified risk loci, but some loci are associated with co-morbidities and are not specific to host-virus interactions. Here, we identify and experimentally validate a link between reduced expression of EXOSC2 and reduced SARS-CoV-2 replication. EXOSC2 was one of 332 host proteins examined, all of which interact directly with SARS-CoV-2 proteins; EXOSC2 interacts with Nsp8 which forms part of the viral RNA polymerase. Lung-specific eQTLs were identified from GTEx (v7) for each of the 332 host proteins. Aggregating COVID-19 GWAS statistics for gene-specific eQTLs revealed an as"],"journal":["bioRxiv : the preprint server for biology"],"pagination":["2022.03.06.483172"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8923113"],"repository":["biostudies-literature"],"pubmed_title":["Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication."],"pmcid":["PMC8923113"],"funding_grant_id":["216596/Z/19/Z","Cooper-Knock/Oct20/899-792","203141/Z/16/Z","P30 DK116074","P50 HL083800","R01 HL122939","UM1 HG009442","10077","BB/S009566/1","NF-SI-0617-10077","S10 OD025212","R01 HL101388"],"pubmed_authors":["Cooper-Knock J","Ferraiuolo L","Moll T","Peden A","Shaw PJ","Azzouz M","Zhang S","Odon V","Franklin J","Souza CDS","Collins MO","Gordon D","Krogan N","Snyder MP","Harvey C","Graves E","Marshall JNG","Rehwinkel J"],"additional_accession":[]},"is_claimable":false,"name":"Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication.","description":"New therapeutic targets are a valuable resource in the struggle to reduce the morbidity and mortality associated with the COVID-19 pandemic, caused by the SARS-CoV-2 virus. Genome-wide association studies (GWAS) have identified risk loci, but some loci are associated with co-morbidities and are not specific to host-virus interactions. Here, we identify and experimentally validate a link between reduced expression of EXOSC2 and reduced SARS-CoV-2 replication. EXOSC2 was one of 332 host proteins examined, all of which interact directly with SARS-CoV-2 proteins; EXOSC2 interacts with Nsp8 which forms part of the viral RNA polymerase. Lung-specific eQTLs were identified from GTEx (v7) for each of the 332 host proteins. Aggregating COVID-19 GWAS statistics for gene-specific eQTLs revealed an as","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-05-18T12:32:28.533Z","creation":"2025-05-18T12:32:28.533Z"},"accession":"S-EPMC8923113","cross_references":{"pubmed":["35291294"],"doi":["10.1101/2022.03.06.483172"]}}